We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+20.24%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$290M
AUM Growth
+$19.5M
Cap. Flow
+$9.29M
Cap. Flow %
3.2%
Top 10 Hldgs %
66.21%
Holding
46
New
10
Increased
7
Reduced
4
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$9.95M
2
APLS
Apellis Pharmaceuticals
APLS
+$8.88M
3
ETNB
89bio
ETNB
+$8.17M
4
VKTX icon
Viking Therapeutics
VKTX
+$6.6M
5
AZN icon
AstraZeneca
AZN
+$6.51M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$16.1M
2
BIIB icon
Biogen
BIIB
+$8.25M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.64M
4
LLY icon
Eli Lilly
LLY
+$4.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
1
Novo Nordisk
NVO
$216B
$55.2M 19.02%
681,812
+39,702
+6% +$3.24M
MRK icon
2
Merck
MRK
$324B
$38M 13.09%
329,200
– –
ARGX icon
3
argenx
ARGX
$57.4B
$18.1M 6.24%
46,438
+10,034
+28% +$3.95M
BIIB icon
4
Biogen
BIIB
$29.9B
$14.9M 5.13%
52,275
-27,725
-35% -$8.25M
AZN icon
5
AstraZeneca
AZN
$263B
$13.7M 4.71%
95,376
+44,222
+86% +$6.51M
ABBV icon
6
AbbVie
ABBV
$458B
$12.2M 4.22%
90,821
– –
MRNA icon
7
Moderna
MRNA
$21.5B
$10.3M 3.55%
84,719
– –
IMGN
8
DELISTED
Immunogen Inc
IMGN
$10.3M 3.53%
+543,358
New +$6.42M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$9.85M 3.4%
51,175
– –
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.63M 3.32%
244,861
-159,754
-39% -$5.64M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$9.38M 3.23%
+102,940
New +$8.88M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.66B
$8.84M 3.05%
+77,162
New +$9.95M
ETNB
13
DELISTED
89bio
ETNB
$8.82M 3.04%
+465,465
New +$8.17M
ROIV icon
14
Roivant Sciences
ROIV
$25.2B
$8.31M 2.86%
824,363
+666,600
+423% +$5.96M
LLY icon
15
Eli Lilly
LLY
$1.07T
$7.59M 2.62%
16,193
-10,735
-40% -$4.5M
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$11.5B
$6.8M 2.34%
78,465
-40,000
-34% -$3.76M
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$121B
$6.44M 2.22%
18,314
+11,200
+157% +$3.77M
AXSM icon
18
Axsome Therapeutics
AXSM
$12.4B
$6.31M 2.18%
+87,848
New +$6.48M
VKTX icon
19
Viking Therapeutics
VKTX
$4.04B
$6.22M 2.14%
383,580
+315,172
+461% +$6.6M
NBIX icon
20
Neurocrine Biosciences
NBIX
$17.7B
$4.24M 1.46%
45,000
– –
BNTX icon
21
BioNTech
BNTX
$22.6B
$4.01M 1.38%
37,108
– –
PTGX icon
22
Protagonist Therapeutics
PTGX
$8.75B
$3.1M 1.07%
+112,340
New +$2.81M
ALNY icon
23
Alnylam Pharmaceuticals
ALNY
$36.3B
$3.03M 1.05%
15,971
– –
TMO icon
24
Thermo Fisher Scientific
TMO
$211B
$2.65M 0.92%
5,088
– –
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.63M 0.91%
41,600
– –
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Artia Global Partners held 46 positions worth $290M, up 7.2% from $271M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Artia Global Partners deployed $9.29M of net new capital in Q2 2023, opening 10 new positions and adding to 7 existing holdings. Its largest new stake was Sarepta Therapeutics: 77,162 shares worth $8.84M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Biogen, an estimated $8.25M trimmed.

  • Artia Global Partners's largest Q2 2023 buy was Sarepta Therapeutics: 77,162 shares worth $8.84M.
  • Artia Global Partners added most to Viking Therapeutics in Q2 2023, an estimated $6.6M increase.
  • Artia Global Partners's biggest Q2 2023 reduction was Biogen, cutting an estimated $8.25M.
  • Artia Global Partners fully exited Karuna Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Artia Global Partners's ten largest holdings make up 66% of its $290M portfolio in Q2 2023.
  • Artia Global Partners opened 10 new positions and closed 12 in Q2 2023.
  • Artia Global Partners's portfolio value rose 7.2% quarter-over-quarter to $290M.

Based on Artia Global Partners's 13F filing for Q2 2023, filed 14 Aug 2023.